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ABSTRACT
Rationale: The recent development of hyperpolarized 13C Magnetic Resonance Spectroscopy (MRS) has 
made it possible to measure cellular metabolism in vivo, in real time. 
Objective: By comparing participants with and without type 2 diabetes (T2DM), we report the first case-
control study to use this technique to record changes in cardiac metabolism in the healthy and diseased
human heart. 
Methods and Results: Thirteen people with type 2 diabetes (HbA1c 6.9±1.0%) and 12 age-matched healthy 
controls underwent assessment of cardiac systolic and diastolic function, myocardial energetics (31P-MRS)
and lipid content (1H-MRS) in the fasted state. In a subset (5 T2DM, 5 control), hyperpolarized [1-
13C]pyruvate MR spectra were also acquired and in five of these participants (3 T2DM, 2 controls), this 
was successfully repeated 45 minutes after a 75g oral glucose challenge. Downstream metabolism of [1-
13C]pyruvate via pyruvate dehydrogenase (PDH, [13C]bicarbonate), lactate dehydrogenase ([1-13C]lactate) 
and alanine transaminase ([1-13C]alanine) was assessed. Metabolic flux through cardiac PDH was 
significantly reduced in the people with type 2 diabetes (Fasted:0.0084±0.0067[Control] vs. 
0.0016±0.0014[T2DM], Fed:0.0184±0.0109 vs. 0.0053±0.0041, p=.013). In addition, a significant increase 
in metabolic flux through PDH was observed after the oral glucose challenge (p<.001). As is characteristic 
of diabetes, impaired myocardial energetics, myocardial lipid content and diastolic function were also
demonstrated in the wider study cohort.
Conclusions: This work represents the first demonstration of the ability of hyperpolarized 13C MRS to non-
invasively assess physiological and pathological changes in cardiac metabolism in the human heart. In
doing so, we highlight the potential of the technique to detect and quantify metabolic alterations in the 
setting of cardiovascular disease.  
Keywords: 

Hyperpolarized magnetic resonance spectroscopy, diabetes mellitus, metabolism, pyruvate dehydrogenase, 

magnetic resonance imaging, diabetic cardiomyopathy.
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Nonstandard Abbreviations and Acronyms: 
ANOVA Analysis of Variance
ATP Adenosine Triphosphate
BMI Body Mass Index 
CMR Cardiac Magnetic Resonance
DNP Dynamic Nuclear Polarization 
ECG Electrocardiogram
EPA Electron Paramagnetic Agent 
FFA Free Fatty Acids
HbA1c Glycated Haemoglobin 
HOMA-IR Homeostatic Model Assessment of Insulin Resistance 
LDH Lactate Dehydrogenase
LV Left Ventricular
LVEDV Left Ventricular End Diastolic Volume 
LVEF Left Ventricular Ejection Fraction 
MR Magnetic Resonance
MRI Magnetic Resonance Imaging 
MRS Magnetic Resonance Spectroscopy
PCr Phosphocreatine
PDH Pyruvate Dehydrogenase 
PET Positron Emission Tomography 
RV Right Ventricular
RVEDV Right Ventricular End Diastolic Volume 
RVEF Right Ventricular Ejection Fraction 
SNR Signal-to-Noise Ratio 
T2DM Type 2 Diabetes Mellitus
INTRODUCTION.
Type 2 diabetes (T2DM), even in the absence of coronary artery disease and hypertension, is 
associated with a 2-5 fold increased risk of heart failure through the development of diabetic 
cardiomyopathy[1]. With the rapid global increase in the prevalence of obesity, and with it T2DM, it is
very likely that there will be a similar increase in the prevalence of diabetic cardiomyopathy. As a result, 
there is a pressing need to improve our understanding of the mechanisms by which diabetes can cause 
heart failure and to develop non-invasive readouts of the mechanisms which underpin this process.   
Several mechanisms have been implicated in the pathogenesis of diabetic cardiomyopathy with changes 
in myocardial structure, calcium signalling, and metabolism all described in animal models[2]. As the
heart requires a vast amount of ATP to maintain contractile function, it is not surprising that there are 
functional consequences if metabolism is altered, and in T2DM, metabolic alteration is inherent to the 
underlying disease process. Although diabetes is characterized by an apparent abundance of substrate 
with increased circulating levels of both free fatty acids (FFA) and glucose, the diabetic myocardium
utilizes almost exclusively FFA for the generation of ATP, and its metabolic flexibility is dramatically
reduced[3]. This arises due to the combination of reduced glucose uptake[4] and increased fatty acid 
oxidation[5], which mediates an inhibition of pyruvate dehydrogenase (PDH) as described by the Randle
cycle[6], resulting in a reduced efficiency of ATP production.
As both systole and diastole are ATP consuming processes, this leads to a proposed mechanism 
whereby reduced glucose oxidation acts, via impaired ATP production, to contribute to the development of 
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diabetic cardiomyopathy, with PDH being the central control point. In line with this, we have recently
shown that by pharmacologically increasing PDH flux, and therefore rebalancing glucose utilization, it is 
possible to reverse the diastolic impairment observable in a rodent model of T2DM[7]. This highlights the 
importance of PDH in this process as a potential therapeutic target.   
Mechanistic insights into diabetic cardiomyopathy to date have, in general, been gained either in
animal models, due to the need for invasive procedures or destructive methods which are not feasible in 
humans, or using positron emission tomography (PET) and magnetic resonance spectroscopy (MRS). 
PET studies have revealed reductions in glucose uptake[8] and increases in fatty acid oxidation[9] whilst 
MRS studies have shown elevated myocardial triglyceride content[10] and impaired myocardial 
energetics[11], confirming to a large extent the findings in animal studies. However, gaining a window
on important changes at the level of PDH has not been possible without invasive biopsies, making this
impractical to assess as a routine biomarker.  
One potential solution to this is 13C MRS. This technique allows a direct evaluation of the activity 
of PDH by measuring the conversion of [1-13C]pyruvate into [13C]bicarbonate (H13CO3-). However, 
although this is scientifically attractive, conventional 13C MRS suffers from an inherently low sensitivity
and low signal to noise ratio, making scan times very long and routine acquisition unfeasible at clinical 
field strengths. This low sensitivity can be overcome using the recent development of hyperpolarized MR 
technology, which can amplify the 13C MRS signal by over 10,000-fold[12]. Using hyperpolarized [1-
13C]pyruvate, physiological changes in PDH flux have been demonstrated in animal models of feeding 
and fasting[13–15]. In addition, changes in cardiac substrate selection in a variety of pathological
situations have been observed[16–18], particularly in diabetes[7,14,19,20]. 
The human applications of this technique are in their infancy, with an initial clinical
demonstration in a study of patients with prostate cancer[21], and two smaller feasibility studies, one in 
the healthy heart[22] and another in the healthy brain[23]. Despite its potential, the assessment of either 
physiological or pathological changes in metabolic flux using hyperpolarized MRS have not yet been
undertaken in the human heart.
As such, the primary aim of the work presented here was to provide the first non-invasive in vivo
demonstration that physiological and pathological changes in PDH flux can be detected in the human 
heart using hyperpolarized [1-13C]pyruvate MRS. By also assessing other hallmarks of diabetic heart 
disease, namely impaired energetics (31P-MRS), myocardial steatosis (1H-MRS), and diastolic 
impairment (echocardiography), we further aimed to determine the additional information that the 
hyperpolarized [1-13C]pyruvate technique can provide in the detection of pathological changes in the
diabetic heart. 
METHODS
The data that support the findings of this study are available from the corresponding author upon reasonable 
request. 
Study cohort and study visit. 
This research was approved by the National Research Ethics Committee service (13/SW/0108) and 
conducted in accordance with the declaration of Helsinki and the Caldicott principles. All data collection
was undertaken at the Oxford Centre for Clinical Magnetic Resonance at the John Radcliffe Hospital, 
Oxford, UK between March 2016 and May 2019. Written informed consent was obtained from all those 
enrolled. Thirteen people with type 2 diabetes and 12 controls were recruited from local advertisements.
DOI: 10.1161/CIRCRESAHA.119.316260  4 
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All participants were aged >18, participants with type 2 diabetes were included if they had a recent HbA1c
between 6 and 9%, no change of oral medications during the previous 3 months and were not on insulin
therapy. Subjects with type 2 diabetes who were taking the oral anti-hyperglycaemic drug, Metformin, were 
asked to refrain from taking their medication for 12 hours before the study to minimise any potential effect 
on cardiac redox state[24].
All study visits began at 7 am following an overnight fast lasting at least 9 hours. Diastolic function 
(echocardiography), systolic function (CMR), myocardial steatosis (1H-MRS) and myocardial energetics 
(31P-MRS) were all assessed in the fasted state. Additionally, hyperpolarized [1-13C]pyruvate MRS was
undertaken immediately before and 45 minutes after a standardized oral glucose tolerance test consisting
of a 75g glucose dose (taken in under 5 minutes; Rapilose®, Galen Ltd, Craigavon, United Kingdom). All 
MR scanning was undertaken at 3T (Tim Trio MR system, Siemens Healthineers, Erlangen, Germany).  
The outline of our study visit is shown in Figure 1 and additional methodological details are given in the 
online supplement. 
Dynamic Nuclear Polarization and production of hyperpolarized [1-13C]pyruvate.
As described in the online supplement, all starting materials were prepared in a Grade A sterile
environment[23] before being loaded into a General Electric SpinLab system (GE Healthcare, Chicago, 
USA) for the process of Dynamic Nuclear Polarization[12]. Sufficient polarization levels were achieved
after 2-3 hours, after which dissolution was undertaken to produce the final hyperpolarized [1-13C]pyruvate 
solution for injection. Solutions were only released for human injection if the following criteria were met:
pH 6.7-8.4, temperature 25.0-37.0°C, polarization ≥ 15%, [pyruvate] 220-280 mM, [EPA] ≤ 3.0 µM, 
appearance: clear, colourless solution with no visible particulate matter. Administration of the
hyperpolarized pyruvate was undertaken through an 18G venous cannula sited in the left antecubital fossa 
at a dose of 0.4 ml/kg and at a rate of 5 ml per second. 
Hyperpolarized MR spectroscopy and data processing. 
Subjects were scanned supine and hyperpolarized 13C MR spectra were acquired using a 2 channel transmit, 
8 channel surface-receive array (Rapid Biomedical, Rimpar, Germany). Hyperpolarized data were acquired
from a mid-ventricular 10 mm axial slice, beginning at the start of the injection, using a pulse-acquire 
spectroscopy sequence acquired ECG-gated to the R-wave with a single slice-selective excitation every 
heartbeat and run for four minutes after injection. Total integrated metabolite-to-pyruvate ratios, known to 
linearly correlate with first-order chemical kinetic rate constants, were calculated by summing the first 60 
seconds worth of spectral data acquired following the initial appearance of the hyperpolarized pyruvate 
resonance in the acquired spectra[25]. Further details are provided in the online supplement. 
Statistical analysis. 
All data was analyzed with the operator blinded to the disease status and metabolic state of the dataset. 
Hyperpolarized datasets, quantified as described above, were analysed with the lme4 and the car packages
in R (v3.6.0, R Foundation for Statistical Computing, Vienna, Austria), with metabolic state and disease
status considered as fixed effects, and subject ID considered as a random effect, and an ANOVA table 
computed. Data were subject to a Shapiro-Wilk normality test and one outlier corresponding to the
[13C]bicarbonate to [1-13C]pyruvate ratio for an unpaired fasted subject with type 2 diabetes with a Z-score
of 9.4, was identified (Grubb’s test p = .003, suggesting that point was an outlier). Data derived from this
participant were excluded from subsequent analysis. No evidence of heteroscedasticity was found in the 
acquired 13C data (Levene’s test, p=.301 for [13C]bicarbonate to [1-13C]pyruvate ratio, p=.635 for [1-
13C]lactate to [1-13C]pyruvate ratio and p=.751 for [1-13C]alanine to [1-13C]pyruvate ratio). This fact may
reflect the comparatively high signal-to-noise ratio of the acquired spectral data, as it is known that the
distribution of metabolite ratios is approximately normally distributed in the high SNR regime[26].  
DOI: 10.1161/CIRCRESAHA.119.316260  5 
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Unless otherwise stated, all other analyses were performed in GraphPad Prism (GraphPad Software, San 
Diego, California, USA) via simple unpaired unequal-variance t-tests with the canonical p<.05 threshold 
for statistical significance. All statistical tests performed are reported in Tables 1 & 2 with the exact p-
values quoted, statistical significance is highlighted by italicising any reported p-values below 0.05.
RESULTS
Baseline population characterisation. 
Healthy controls (n=12) and people with type 2 diabetes (n=13) were recruited with no difference 
in age (controls – 50.3±11.4 years, people with type 2 diabetes – 55.2±5.8 years, p=.190) or sex (controls
– 8 male / 4 female, people with type 2 diabetes – 11 male, 2 female). Participants with type 2 diabetes had 
significantly higher body mass index (BMI) than controls (22.6±3.0 vs. 29.7±6.8, p=.003), but baseline 
myocardial structural characteristics assessed by cine-MRI including left ventricular ejection fraction
(60±4% vs. 57±6%, p=.228), indexed left ventricular end-diastolic volume (82±12 ml/m2 vs. 79±15 ml/m2, 
p=.577) and myocardial mass index (64±10 g/m2 vs. 62±11 g/m2, p=.658), were not different between
groups (Table 1). Participants with type 2 diabetes were confirmed to be more insulin resistant than the 
controls (HOMA-IR 1.3±0.8 vs. 4.3±2.5, p=.005), with higher fasting blood sugar. Five controls and five 
people with type 2 diabetes from within this cohort then went on to have fasting [1-13C]pyruvate 
hyperpolarized MRS, with five (two control, three T2DM) receiving successful repeat [1-13C]pyruvate
hyperpolarized MRS 45 minutes after glucose ingestion. Again, this smaller hyperpolarized MRS group 
was well matched for age and myocardial structural characteristics (Table 1). Example data acquired from 
our study population are shown in Figure 2, demonstrating the breadth of metabolic and structural 
parameters acquired in a single scanning session. 
DOI: 10.1161/CIRCRESAHA.119.316260  6 
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Table 1: Characteristics of study population 

Study Population
	
General 

Age (years) 

Weight (Kg)
	
BMI (Kg/m2) 

HbA1c (%) 

HOMA IR
	
Fasting Glucose (mmol/l) 

Medication
ACE-Inhibitor

Statin 

Metformin 

Sulfonylurea 

Calcium Channel Blocker

Thiazide Diuretic
	
Asprin 

Liraglutide
	
Sitagliptin 

Echocardiography 
E/A
	
E/e’ (medial) 

E/e’ (lateral)
	
E/e’ (mean)
	
CMR 
LVEF (%)
	
LVEDV Index (ml/m2) 

LV Mass Index (g/m2) 

RVEF (%) 

RVEDV Index (ml/m2) 

Spectroscopy 
PCr/ATP 

Myocardial Lipid Content
	
(% of water) 

13C MRS Only Group 
Age (years) 

Weight (Kg)
	
BMI (Kg/m2) 

E/e’ (mean) 

PCr/ATP 

Myocardial Lipid Content
	
(% of water) 

Control (n=12) Diabetic (n=13) p-Value
	
50.3 ± 11.4 
68.0 ± 13.1 
22.6 ± 3.0 
4.9 ± 0.3
1.3 ± 0.8 
4.8 ± 0.7
0
0 
0 
0 
0
0 
0
0 
0 
1.3 ± 0.4
6.3 ± 2.0 
5.1 ± 1.8
5.7 ± 1.7
60 ± 4
	
82 ± 12 

64 ± 10
	
54 ± 4 

93 ± 8
	
1.94 ± 0.21 

1.59 ± 0.88 

Control (n=5) 

49.2 ± 13.1 

72.1 ± 7.4 

22.6 ± 1.7 

4.7 ± 1.1
	
2.03 ± 0.15 

1.29 ± 0.63 

55.2 ± 5.8 .190 
93.7 ± 17.7 <.001
29.7 ± 6.8 .003 
6.9 ± 1.0 <.001
4.3 ± 2.5 .005 
7.9 ± 2.7 .006 
6 -
9 -
11 -
5 -
2 -
2 -
2 -
1 -
1 -
1.0 ± 0.3 .127 
8.1 ± 1.4 .025 
6.3 ± 1.8 .149 
7.2 ± 1.4 .040 
57 ± 6 .228 
79 ± 15 .577 
62 ± 11 .658 
54 ± 6 .934 
84 ± 16 .095 
1.71 ± 0.30 .042 
3.05 ± 1.96 .026 
Diabetic (n=5)
52 ± 5.2 .668 
99.2 ± 13.9 .005 
31.1 ± 6.1 .017 
6.6 ± 1.2 .030 
1.75 ± 0.35 .138 
3.40 ± 2.26 .079 
DOI: 10.1161/CIRCRESAHA.119.316260  7 
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Injected hyperpolarized [1-13C]pyruvate solution product specifications. 
Hyperpolarized [1-13C]pyruvate solution injections were well tolerated by all subjects with no side 
effects reported. Ten participants (five controls, five T2DM) received a total of 15 injections meeting the
release criteria. The quality of these were highly standardized; mean (±SD) pyruvate concentration was 
239±8 mM, residual EPA 1.1±0.7 µM, pH 7.7±0.4, temperature 34±1°C and polarization 34±13%. The 
mean polarization time was 150±30 minutes and dissolution to injection times were all less than 90 seconds.  
Hyperpolarized 13C magnetic resonance spectroscopy. 
Acquired hyperpolarized spectra were of high quality with peaks corresponding to
[13C]bicarbonate, 13CO2, [1-13C]lactate and [1-13C]alanine (the downstream metabolites of [1-13C]pyruvate), 
clearly visible and appearing 2-3 seconds after the ventricular [1-13C]pyruvate resonance. Example fed and
fasted summed spectra from both a control and subject with type 2 diabetes are shown in Figure 3, with
typical time courses of substrate and metabolite signal intensities for a control and a subject with type 2
diabetes also shown. A summary of time-integrated metabolite to substrate ratios derived from the in vivo
hyperpolarized 13C MRS data can be found in Table 2.
Table 2: Time-integrated metabolite to substrate ratios derived from hyperpolarized 13C MR data
Control (n=5) Diabetic (n=5) p-Value
Fasted 
(n=5)
Fed 
(n=2)
Fasted 
(n=5)
Fed 
(n=3)
Metabolic 
state Diseased state Interaction 
Bic/Pyr 
(x10-2) 
0.84 ±
0.67 
1.84 ±
1.09 
0.16 ±
0.14 
0.53 ±
0.41 <.001 .013 .040 
Lac/Pyr 
(x10-2) 
5.16 ±
1.52 
5.94 ±
2.01 
8.51 ±
1.38 
10.53 ±
1.38 .072 <.001 .455 
Bic / Lac 0.15 ±0.10 
0.30 ±
0.08 
0.02 ±
0.02 
0.05 ±
0.03 <.001 <.001 .008 
Ala/Pyr 
(x10-2) 
3.17 ±
1.11 
3.70 ±
2.03 
3.82 ±
1.05 
4.74 ±
0.66 .077 .257 .690 
The [13C]bicarbonate to [1-13C]pyruvate ratio, shown previously to linearly correlate with 
enzymatic flux through PDH, was significantly reduced by diabetes (5.3-fold reduction when fasted and
3.5-fold reduction when fed, p=.013). Conversely, the [1-13C]lactate to [1-13C]pyruvate ratio, reflecting 
exchange through LDH, was increased by diabetes (1.6-fold increase when fasted and 1.8-fold increase
when fed, p<.001). As a marker of the balance between glycolytic and oxidative carbohydrate 
metabolism[27], the ratio of [13C]bicarbonate and [1-13C]lactate signals showed a significant reduction in 
relative carbohydrate oxidation in the subjects with type 2 diabetes (7.5-fold reduction when fasted and 6-
fold reduction when fed, p<.001). Transamination of [1-13C]pyruvate to [1-13C]alanine was not different 
between subjects with type 2 diabetes and controls (p=.257). Comparisons of enzymatic flux data as 
assessed by hyperpolarized MRS are summarized in Figure 4. 
Hyperpolarized MRS also successfully demonstrated Randle cycle associated increases in PDH
flux after feeding with flux significantly increased 45 minutes after the oral administration of 75 g of 
glucose (p<.001). Importantly, this increase was discernible not only in controls (2.2-fold increase), but 
also in the subjects with type 2 diabetes (3.3-fold increase), in spite of the impaired basal PDH flux we have
demonstrated in this condition. There were no statistically significant differences in LDH flux (p=.072) or
the rate of pyruvate transamination (p=.077) between the fasted and fed states.
DOI: 10.1161/CIRCRESAHA.119.316260  8 
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31P and 1H magnetic resonance spectroscopy. 
As expected, within the wider study population, diabetes significantly impaired cardiac diastolic 
function (mean E/e’ 5.7±1.7 vs. 7.2±1.4, p=.040), myocardial energetics (PCr/ATP 1.94±0.21 vs. 
1.71±0.30, p=.042) and increased myocardial triglyceride content (1.59±0.88 vs. 3.05±1.96, p=.026). The
effect sizes for these differences (E/e’=0.963, PCr/ATP=0.888, myocardial triglyceride content=0.961, 
G*Power 3.1) were all lower than the effect sizes calculated for the differences observed between the fasted
controls and the subjects with type 2 diabetes from the 13C enzymatic flux data reported above 
(bicarbonate/pyruvate = 1.405, lactate/pyruvate = 2.308, bicarbonate/lactate = 1.803). This means that, 
when comparing two groups with a simple Students t-test, to observe the differences seen here at a p-value
of 0.05 with a power of 90% would require group sizes of 24, 28 and 24 for E/e’, PCr/ATP and myocardial 
triglyceride content respectively versus group sizes of 12, 6 and 8 for bicarbonate/pyruvate, lactate/pyruvate 
and bicarbonate/lactate respectively (G*Power 3.1).  
Weak correlations were observed between the PCr/ATP ratio and the metabolic parameters
assessed by hyperpolarized MRS (i.e. positive correlations between PCr/ATP and the bicarbonate/pyruvate, 
alanine/pyruvate and bicarbonate/lactate ratios and a negative correlation between PCr/ATP and the 
lactate/pyruvate ratio, but these failed to reach statistical significance, Supplementary Figure I).
DISCUSSION
In the setting of the rapid global increase in T2DM and its relationship with heart failure, increasing 
our understanding of the metabolic changes that occur in diabetes is becoming increasingly important. 
Using a hyperpolarized [1-13C]pyruvate tracer, we have shown that, following glucose ingestion, the
myocardium increases pyruvate oxidation through PDH (PDH Flux), in line with the metabolic alterations
proposed by the Randle cycle[6]. In addition, we have also shown in patients with type 2 diabetes and
diastolic dysfunction that PDH flux is reduced, similarly to alterations seen in animal models[7,20]. This, 
therefore, represents the first non-invasive demonstration of physiological and pathological changes in PDH 
flux in the human heart using hyperpolarized MRS. Furthermore, we have used 31P and 1H spectroscopy to
confirm that, in the presence of reduced PDH flux, the diabetic myocardium has reduced myocardial 
energetics (PCr/ATP ratio) and increased myocardial triglyceride content. This is the first human study to
use the multi-nuclear combination of 1H, 31P and 13C MR spectroscopy to interrogate myocardial 
metabolism and confirms the potential of hyperpolarized MRS for translation to the clinical quantification
of metabolic alterations in cardiac pathology.
Pyruvate dehydrogenase flux. 
Our demonstration that the fasted heart increases PDH flux after an oral glucose challenge is
consistent with the Randle cycle and confirms previous hyperpolarized [1-13C]pyruvate experiments in
mice[13], rats[14] and pigs[15]. Whilst this is an expected result, it is the first demonstration in humans 
that hyperpolarized [1-13C]pyruvate MR can detect physiological changes in myocardial metabolism, an
important milestone in its clinical translation. 
As the post-glucose scan was undertaken ~one hour after the initial fasted scan, there is the 
possibility that the injected pyruvate dose from the first scan may also have played a part in the increased
PDH flux observed. However, it seems unlikely that the ~1 g dose of pyruvate given would have had a
significant impact on top of the 75g of glucose provided. The variation in PDH flux observed between the 
fed and fasted states also illustrates that, when considering myocardial metabolic readouts, there is a need
to standardize (or at least establish) the prevailing metabolic conditions under which they are made. To
DOI: 10.1161/CIRCRESAHA.119.316260  9 
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date, animal models have used glucose loading prior to hyperpolarized studies to maximize baseline PDH
flux, increasing the power of studies aiming to detect pathological changes.   
In contrast to the normal heart, which has metabolic flexibility, the diabetic heart becomes almost 
exclusively reliant upon fatty acids as its main catabolic substrate. This overreliance on fat metabolism is 
likely underpinned by an impaired ability to uptake glucose and oxidize the resulting pyruvate through
PDH. Indeed, animal models of diabetes have shown PDH inhibition both ex vivo[28] and in vivo[14]. In
line with this, we have shown here in people with type 2 diabetes, that myocardial PDH flux is reduced 
compared to the normal healthy heart. Minimal discernible flux through PDH was observed in the fasted 
diabetic state, with only a small increase demonstrated after glucose loading, however, our findings show
that hyperpolarized [1-13C]pyruvate studies aimed at measuring alterations in PDH flux in patients with
type 2 diabetes are indeed feasible. 
Linking altered substrate metabolism to altered function. 
As diastole is more susceptible to ATP shortage than systole, alterations in substrate selection may
act via reduced efficiency of ATP production initially as diastolic dysfunction, which is an almost universal 
finding in type 2 diabetes[29,30]. In line with this, we have shown here that the diabetic myocardium has 
reduced pyruvate oxidation (reflective of reduced glucose utilization), increased triglyceride deposition
(suggestive of excess fatty acid uptake), reduced myocardial energetics (with reduced PCr/ATP) and 
diastolic dysfunction. As the diabetic phenotype in this study was not advanced or severe (we excluded
subjects requiring exogenous insulin; average HbA1c was 6.9%), this highlights the metabolic inflexibility
of the cardiomyocyte in the setting of lower grades of insulin resistance, and also the ability of 
hyperpolarized MR to detect early changes in myocardial metabolism in diabetes.  
Lactate dehydrogenase flux. 
Incorporation of the 13C label into [1-13C]lactate in our acquired spectra was significantly higher in 
subjects with type 2 diabetes in both fasted and fed states suggesting raised LDH flux in this group. 
Although it could be assumed that given [1-13C]pyruvate flux through PDH was lower, that LDH flux, and
therefore the lactate pool size[31], would be reciprocally increased, this interpretation may be too simplistic. 
Other factors should be considered, for example it has previously been demonstrated that the
antihyperglycemic agent, Metformin, has an effect on cardiac redox state that elevates the observed lactate
signal[24]. To minimise this effect, the subjects with type 2 diabetes studied were asked to refrain from 
taking their Metformin on the day of the study. However, we cannot exclude the possibility that a chronic 
effect of their Metformin treatment may have contributed to the elevated lactate signal observed.  
In addition, the myocardial [1-13C]lactate signal following injection of [1-13C]pyruvate has proven
much more diffuse in hyperpolarized short axis images of the both the human[22] and pig heart[32] with a
large contribution from the blood pool. Therefore, [1-13C]lactate generated in, and effluxed from, the liver 
may also be contaminating the cardiac readouts[33]. As such, we must be cautious in interpreting the exact 
derivation of the increased lactate signal from non-localized spectra. With metabolite imaging now possible 
in the human heart[22], this will aid in the localization of the lactate signal and discern whether or not its 
origin is myocardial. 
Alanine aminotransferase flux.
In ex vivo models, the rate of pyruvate transamination has been shown to increase proportionally
as pyruvate perfusate concentration increases. Labelled alanine is thus a direct measure of the intra-cellular 
availability of labelled pyruvate and the alanine signal has therefore been suggested as an alternative
normalization standard (as opposed to the pyruvate signal)[34]. Relative stability of [1-13C]alanine signals 
DOI: 10.1161/CIRCRESAHA.119.316260  10 
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in our study, and lack of difference between groups, suggests cellular bioavailability of administered [1-
13C]pyruvate was uniform, and not a potential confounder of the variation of enzymatic fluxes seen. 
Wider translation to clinical practice.
The technology of dissolution DNP is still in its infancy. The first demonstration of clinical 
translation was published in 2013 using a prototype polarizer located inside a cleanroom to prepare sterile
injections for prostate cancer patients[21]. The SpinLab is the clinical grade second generation of polarizer 
suitable for preparing sterile injections outside of a controlled pharmaceutical facility, and currently 10 sites 
worldwide are injecting hyperpolarized compounds in early-phase clinical trials. Using this clinical system,
we have demonstrated the first step in the clinical translation into cardiovascular disease characterization 
through the observation of metabolic flux changes in the normal and the diabetic human heart. While 
technically challenging, leading in part to our work being performed on a comparatively small number of 
subjects, the large effect size of metabolic dysregulation in disease is such that significant differences in 
myocardial metabolism, known extensively to exist from several decades of previous animal 
experimentation, as well as the effects of novel therapies, can be conclusively demonstrated in the human
heart. Future studies should build on this proof-of-principle to explore the impact of other cardiovascular 
diseases, as well as the role that possible confounding factors (such as age, sex, medication use) might have
on cardiac metabolism. 
As hyperpolarized 13C-imaging allows the in vivo visualization of cardiac metabolism, it has major 
advantages over current non-invasive imaging techniques. Hyperpolarized scans are fast (<2 mins), have 
no ionizing radiation, and, due to the ability to simultaneously acquire standard MRI acquisitions, have the 
potential to directly assess perfusion, ischemia, viability, and altered substrate selection in one imaging 
session. However, the technique does have some limitations. Firstly, the rapid decay of the hyperpolarized
signal (i.e. the T1 of hyperpolarized [1-13C]pyruvate in solution has been measured to be 67.3 ± 2.5 s at 
3T[35]) leads to the requirement to undertake the hyperpolarization process adjacent to the MRI system 
and to inject the hyperpolarized tracer immediately after production. Whilst this offers some technical
challenges, the work reported here and by others[21–23] demonstrates that these challenges, as with short-
lived PET tracers, can be overcome. 
Secondly, in contrast to PET systems, which are capable of measuring picomolar amounts of 
radiolabelled molecules, hyperpolarized pyruvate scans require injection of the tracer at millimolar
concentrations. It has previously been suggested that this “supra-physiological” dose of pyruvate may
impact the metabolic processes that are being assessed. However, pre-clinical work in animals has shown 
that similar doses (~320 mol/kg in previous rat studies versus the ~140 mol/kg used in this work) leads 
to maximum plasma pyruvate concentrations of approximately 250 µM, equivalent to physiological
pyruvate concentrations reached during exercise or with dietary interventions[34]. In addition, pre-clinical
studies have demonstrated tight correlations between in vivo hyperpolarized MRS measurements of PDH 
flux and ex vivo measurements of PDH enzyme activity[34].  
Whilst the work described here was undertaken at 3T, there are advantages and disadvantages to
undertaking hyperpolarized experiments at different field strengths. Higher field strengths provide
increased spectral separation between different metabolites and the subsequent benefits in quantification 
and selection of different metabolites for spectral imaging that this brings. Alternatively, the longitudinal 
relaxation times of hyperpolarized agents are generally longer at lower field strengths[35] and there is 
improved B0 homogeneity which will improve spectral linewidths. As such, 3T seems a reasonable
compromise between these competing factors for such initial proof-of-concept studies. 
DOI: 10.1161/CIRCRESAHA.119.316260  11 
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In conclusion, this study provides the first demonstration of the ability of hyperpolarized pyruvate
to non-invasively assess physiological and pathological changes in pyruvate dehydrogenase flux in the
human heart. In doing so, we highlight the potential of the technique to assess metabolic alterations in a 
range of cardiovascular diseases.
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FIGURE LEGENDS
Figure 1: Outline of our typical study visit. The fasting stipulation in our study restricted our 
recruitment to what can be considered a fairly mild phenotype of diabetes – only those patients receiving 
oral medication. The total study visit was under three hours; however, each hyperpolarized MRS scan 
took only a few minutes, meaning its addition to the normal length of routine MR protocols would be
insignificant. 
Figure 2: Example data collected during our study from a recruited control (top row) and a 
subject with type 2 diabetes (bottom row). In characterizing our recruits both structurally (CMR / 
Echo) and metabolically (31P MRS, 1H MRS, hyperpolarized 13C  MRS),  we collate the most  
comprehensive study of the diabetic cardiac phenotype to date.
Figure 3: Representative examples of hyperpolarized MR spectra from both a healthy control and
a subject with type 2 diabetes in both the fasted and fed states, with 13C containing downstream
metabolites labelled. The  [13C]bicarbonate resonance is visibly reduced in the subject with type 2
diabetes with increases seen during feeding in both controls and subjects with type 2 diabetes. Time
courses of the normalized signal amplitudes of downstream 13C-labelled metabolic products of
administered [1-13C]pyruvate (shown in blue), in both a control and a subject with type 2 diabetes are
also shown. 
Figure 4: Plots of metabolic flux data for each metabolic product of administered [1-
13C]pyruvate. Flux through PDH (Bicarbonate, A) is reduced in the subjects with type 2 diabetes
(p=.013), with increases seen during feeding (p<.001, E). Levels of [1-13C]lactate were significantly 
higher in the hearts of people with type 2 diabetes (p<.001, B) with no change observed upon feeding
(F). The ratio of bicarbonate and lactate was significantly lower in the subjects with type 2 diabetes
(p<.001, C) and was elevated by feeding (p<.001, G). No significant differences in [1-13C]alanine were
seen across all injections (D,H). † p<.05 in subjects with type 2 diabetes vs. controls, * p<.05 in fasted 
subjects vs. fed, ‘x’ indicates the data point excluded as an outlier.
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NOVELTY AND SIGNIFICANCE
What Is Known? 
• The way the heart turns fuels (e.g. fats, glucose) into energy, called metabolism, is altered in many 
types of heart disease.
• However, we have very limited techniques available to allow us to measure metabolism in patients. 
What New Information Does This Article Contribute? 
• This article demonstrates the first use of a new technique, called hyperpolarized 13C magnetic resonance 
imaging (MRI), for measuring changes in cardiac metabolism in healthy controls and people with
diabetes. 
• We show here that hyperpolarized 13C MRI can detect increases in the metabolism of carbohydrates 
(e.g. glucose) when people go from being fasted to fed and also that carbohydrate metabolism is 
significantly reduced in the diabetic heart. 
Alterations in cardiac metabolism are a hallmark of many cardiovascular diseases but current imaging 
techniques have a limited ability to study cardiac metabolism non-invasively. The emerging technique 
of hyperpolarized 13C MRI offers >10,000-fold gains in the sensitivity of MRI for the assessment of
cardiac metabolism. This work demonstrates the first step in the clinical translation of this exciting new 
technology into cardiovascular disease characterization through the observation of metabolic flux
changes in the normal and the diabetic human heart. By showing that metabolic flux through the key
regulatory enzyme, pyruvate dehydrogenase, is increased in the transition from the fasted to the fed state
and is significantly reduced in the diabetic heart, this work represents the first demonstration of the ability
of hyperpolarized 13C MRI to non-invasively assess physiological and pathological changes in cardiac
metabolism in the human heart. As hyperpolarized 13C MRI allows the in vivo visualization of cardiac 
metabolism, it has major advantages over current non-invasive imaging techniques. Hyperpolarized 13C 
MRI scans are fast (<2 mins), have no ionizing radiation, and, due to the ability to simultaneously acquire 
standard MRI acquisitions, have the potential to directly assess perfusion, ischemia, viability, and altered 
substrate selection in one imaging session. 
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